Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | RCOR3 | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-08 |
mRNA | VANGL2 | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-08 |
mRNA | KCNRG | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-08 |
mRNA | TNFRSF12A | CTRPv2 | pan-cancer | AAC | -0.22 | 4e-08 |
mRNA | FHL2 | CTRPv2 | pan-cancer | AAC | -0.19 | 4e-08 |
mRNA | KCNAB3 | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-08 |
mRNA | EFNB3 | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-08 |
mRNA | ZNF316 | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-08 |
mRNA | HNRNPK | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-08 |
mRNA | ZNF766 | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-08 |